Kynmobi FDA Approval History
FDA Approved: Yes (First approved May 21, 2020)
Brand name: Kynmobi
Generic name: apomorphine hydrochloride
Dosage form: Sublingual Film
Company: Sunovion Pharmaceuticals Inc.
Treatment for: Parkinson's Disease
Kynmobi (apomorphine sublingual film) is a novel formulation of the approved dopamine agonist apomorphine for the on-demand management of OFF episodes associated with Parkinson’s disease (PD).
Development Timeline for Kynmobi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.